Platform technology
Next-Gen Oncology Platform Disrupting the Efficacy-Toxicity Trade-Off
Sagitta® Bir and Sagitta® Dui are discovered to address the challenge of having an optimum therapeutic index for cancer treatment with biodegradable conjugation platforms that reinforce ideal performances in terms of efficacy, PK and manufacturability.
Sagitta®
Next-Gen Oncology Platform Disrupting the Efficacy-Toxicity Trade-Off
Sagitta® Bir and Sagitta® Dui are discovered to address the challenge of having an optimum therapeutic index for cancer treatment with biodegradable conjugation platforms that reinforce ideal performances in terms of efficacy, PK and manufacturability.
The lead candidate: RS-0139
The lead candidate: RS-0337
The lead candidate: RS-0139
Upon contact with water, Sagitta® Bir backbone wraps around the payload, ensuring formation of a water-soluble nanocarrier.
The lead candidate: RS-0337
Upon contact with water, Sagitta® Dui forms a micellar nanoparticle, encapsulating the second payload.
Sagitta® Radix’s design allows for precise targeting of disease sites via monoclonal antibodies (mAbs) or peptides for theranostic applications.
Sagitta® disrupts the efficacy-toxicity trade-off and delivers safer, more effective chemotherapy to millions, by precisely targeting the drug molecules
- Smart medicine with active tumor targeting
- Improved pharmacokinetics
- Salvaging failed drugs through conjugation to patented platforms
- Clinically validated platform ready today
- Increased efficacy through better tumor accumulation, reduced side effects
- Higher and longer exposure to medicine
- Resetting patent expiry dates via making prodrugs
- Can partner to unlock the AI-driven drug development trend
Efficacy & Specificity
Efficacy & Specificity
· Synergistic therapeutic effect ·
· Higher accumulation ·
Translatability
Translatability
· Predictable translation to human ·
Tolerability
Tolerability
· Enhanced Permeability & Retention effect ·
· Selective release ·
· Biologic stimuli driven release ·
Manufacturability
Manufacturability
· High purity ·
· Scalable for clinical GMP batches ·
- Smart medicine with active tumor targeting
- Improved pharmacokinetics
- Salvaging failed drugs through conjugation to patented platforms
- Clinically validated platform ready today
- Increased efficacy through better tumor accumulation, reduced side effects
- Higher and longer exposure to medicine
- Resetting patent expiry dates via making prodrugs
- Can partner to unlock the AI-driven drug development trend
Efficacy & Specificity
· Versatile structure ·
· Synergistic therapeutic effect ·
· Higher accumulation ·
Translatability
· Pharmacokinetic parameters ·
· Predictable translation to human ·
Tolerability
· Reduced side effect profile ·
· Enhanced Permeability & Retention effect ·
· Selective release ·
· Biologic stimuli driven release ·
Manufacturability
· Proven GMP production record ·
· High purity ·
· Scalable for clinical GMP batches ·
